BERTIS, a proteomics technology company that uses bioinformatics and proteomics to find key biomarkers for detecting cancers and various diseases. Bertis stands out in the field of quantitative proteomics with its comprehensive technology platform. They encompass the entire process, from identifying protein biomarkers to developing diagnostic solutions. This allows them to conduct in-depth research and development on diagnostic solutions for various cancers and major diseases.
Early diagnosis of Pancreatic Cancer
Pancreatic cancer is the worst cancer with a 5-year relative survival rate of only 11%. While effective early diagnostic methods for pancreatic cancer are currently lacking, BERTIS is developing a technology that enables early diagnosis of pancreatic cancer with a small blood sample. Through research, we have identified 10 protein biomarkers as a diagnostic marker panel for pancreatic cancer. Following algorithm development and validation, we have uncovered a combination of markers that demonstrates a high accuracy of 98% and is applicable in clinical settings. The number of deaths and new cases with pancreatic cancer are increasing every year worldwide and it is a fatal cancer in which the number of deaths per new cases in a year is significantly low when compared with other cancers.
Development Process
The pancreas is located deep inside the body; behind the stomach, connected to the duodenum and bile ducts, adjacent to the spleen. This location makes pancreatic cancer difficult to detect and hence spreads quickly throughout the body. Nearly half of patients (52%) are diagnosed with pancreatic cancer in the distant metastasis stage when cancer cells have already spread to other organs. In this condition, the relative survival rate is only 3.1%. Early diagnosis is of the utmost importance with this cancer.
Click here to contact Bertis
View more: World’s First Proteomics-Based Blood Test Solution for the Early Diagnosis of Breast Cancer
